Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform Dexcom GenAI-enabled technology will leverage Google Cloud’s Vertex AI platform and ...
DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...
Dexcom ($DXCM) offered investors a glimpse of its high-profile partnership with Google Life Sciences to develop a next-generation continuous glucose monitor that ...
DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S.
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the launch of updated t:slim X2™ insulin pump ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
The FDA has approved Dexcom's G7 wearable for glucose monitoring for people with all types of diabetes, and the company expects it hit pharmacy shelves in 2023. The wearable is now cleared in the US ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback